News

The insulin glargine product is the first insulin treatment approved through the European Medicines Agency’s (EMA’s) biosimilar pathway and the fourth diabetes product approved in the European Union

Patheon, the pharmaceutical services business unit of DPx Holdings B.V., is a global provider of development and commercial manufacturing services for prescription drugs. "With this Patheon agreement completed

Under the terms of the agreement, Sutro will provide its Xpress CF technology for the rapid and reproducible expression of antibodies and antigens by the Wells Lab for

The US patent no. 8,808,679 provides coverage for anti-tumor payloads and customized linkers used in the company’s Dolaflexin conjugation platform. The second US patent no. 8,815,226 expands its

As part of the deal, Lee’s has secured an exclusive license and right from Abiogen to register, import, market, distribute and sell the Cholecalciferol finished products such as

Currently, EVK-001 is in a Phase III clinical trial for the relief of symptoms related with acute and recurrent gastroparesis in women with diabetes mellitus. A total of

As part of the deal, OnCore will pay NeuroVive an initial upfront payment, development and sales milestones as well as royalties based on future sales. The total value

Endometriosis occurs when cells that line the uterus or womb grow elsewhere in the body. SR16234, a drug candidate of SRI, is a member of a class of

"The astronomical rate of obesity is unfortunate, but as a business; it’s something ANAS can capitalize on. We can’t control the world’s eating and activity habits but that